Stratified Risk Score Developed for Burkitt's Lymphoma

Brown University researchers have developed a stratified risk score for patient prognosis in the treatment response of patients with Burkitt’s lymphoma.

The team of researchers was lead by Dr. Jorge Castillo, an assistant professor of medicine at the Warren Alpert Medical School of Brown University and a hematology/oncology specialist at Rhode Island Hospital.

The study

Castillo and colleagues looked at the records of 2,284 Burkitt's patients during a period of 11 years.

Using factors including survival rates, age, race, cancer location and cancer stage they created a risk score. Patients with the lowest score have a 7 of 10 chance of survival with treatment, while patients with a 10 have less than 3 in 10 chance of survival.

The findings

Investigators determined that age plays a huge role in survival; notably, patients older than 80 have a five times higher risk of dying from the disease than patients aged 20-39 years. Furthermore, advanced stage Burkitt's (Stage IV) patients are almost two and a half times at greater risk of of dying compared to those in early stages (Stage I).

Looking at the positive

Some good news included the fact that survival rates have been boosted substantially over time. For the younger patients, the rate of overall survival in 1998 was 34.7 percent compared to 62.1 percent today for this same patient population.

Oncologists can use this score to help them make treatment decisions as well as inform patients on their choices.

Burkitt's lymphoma is a rare subtype of non-Hodgkin's lymphoma. It is of B-cell origin and represents fewer than 2 percent of all lymphoid cancers.

Source: doctortipster

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap